Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno‐associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation
Journal of Ophthalmology · 2024-01 · 2024 (1)
DOI: 10.1155/2024/5487973 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Ophthalmology, online erschienen am 09.09.2024. Verfasst von Mengzhen Xie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology West China Hospital Sichuan University, Chengdu 610041, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Science and Technology of Sichuan Province, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Corneal diseases represent 5.1% of all eye defects and are the fourth leading cause of blindness globally. Corneal neovascularization can arise from all conditions of chronic irritation or hypoxia, which disrupts the immune‐privileged state of the healthy cornea, increases the risk of rejection after keratoplasty, and leads to opacity. In the past decades, significant progress has been made for neovascular diseases of the retina and choroid, with plenty of drugs getting commercialized. In addition, to overcome the barriers of the short duration and inadequate penetration of conventional formulations of antivascular endothelial growth factor (VEGF), multiple novel drug delivery systems, including adeno‐associated virus (AAV)‐mediated transfer have gone through the full process of bench‐to‐bedside translation. Like retina neovascular diseases, corneal neovascularization also suffers from chronicity and a high risk of recurrence, necessitating sustained and efficient delivery across the epithelial barrier to reach deep layers of the corneal stroma. Among the explored methods, adeno‐associated virus‐mediated delivery of anti‐VEGF to treat corneal neovascularization is the most extensively researched and most promising strategy for clinical translation although currently although, it remains predominantly at the preclinical stage. This review comprehensively examines the necessity, benefits, and risks of applying AAV vectors for anti‐VEGF drug delivery in corneal vascularization, including its current progress and challenges in clinical translation.
Autor:innen und Institutionen
- Department of Ophthalmology West China Hospital Sichuan University, Chengdu 610041, China.
- Beijing Institute of Ophthalmology Beijing Tongren Eye Center Beijing Tongren Hospital Capital Medical University Beijing Ophthalmology and Visual Sciences Key Laboratory, Beijing, China.
- School of Life Science and Engineering Southwest Jiaotong University, Chengdu, Sichuan, China.
- Georgia State University, Atlanta, GA 30302, USA.
ORCID-Profile: Lixiang Wang, Ke Ma, Jing Tang
Förderung
- Department of Science and Technology of Sichuan Province
- West China Hospital, Sichuan University
Zitieren
APA
Xie, M., Wang, L., Deng, Y., Ma, K., Yin, H., Zhang, X., Xiang, X., & Tang, J. (2024). Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno‐associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation. Journal of Ophthalmology, 2024(1). https://doi.org/10.1155/2024/5487973
Vancouver
Xie M, Wang L, Deng Y, Ma K, Yin H, Zhang X, et al. Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno‐associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation. Journal of Ophthalmology. 2024;2024(1). doi:10.1155/2024/5487973
BibTeX
@article{Xie2024,
author = {Xie, Mengzhen and Wang, Lixiang and Deng, Yingping and Ma, Ke and Yin, Hongbo and Zhang, Xiaolan and Xiang, Xingye and Tang, Jing},
title = {Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno‐associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation},
journal = {Journal of Ophthalmology},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/2024/5487973}
}
EUVIMED